
Agreed. Must clear before thinking of entering.  

ricourean ( Date: 04-Jul-2012 10:05) Posted:
|
Need this to clear the 1.20-1.23. Believe will at least go to test the 1.23.
can short if the support at $1.09 has bn broken down...
New123 ( Date: 03-Jul-2012 23:36) Posted:
|
I didn't short. not vested
xinru86 ( Date: 03-Jul-2012 23:13) Posted:
|
New, think better dont try to short this one, it got a green bar with double average volume.  
New123 ( Date: 03-Jul-2012 11:57) Posted:
|
  Hope you don short.  Weak holders have all sold out.  Expect it to go higher. The brave still holding their shorts.
New123 ( Date: 03-Jul-2012 11:57) Posted:
|
hehe i bought at 1.13 a couple of weeks ago :) 
 
stockmarketmind ( Date: 03-Jul-2012 12:37) Posted: |
:) should buy more at the bottom at 1.12-1.14
yiming2000 ( Date: 03-Jul-2012 09:50) Posted: |
So those who bought biosensor after I posted should have made! Congrats!
stockmarketmind ( Date: 26-Jun-2012 19:32) Posted:
|
Biosensor got 6 existing warrants.
4 of them expired this yr: 5/9, 2/10, 1/11
Guys must know why you wanna buy dont let ppl chant you buy, you buy hor.   Every purchase must come with a valid reason dont from our research k 
dead cat bounce..think it may go down ... 
Our Thursday nite US will come out a series of data: PMI, unemployment claims etc so do you what to try your luck to long any counter now?
 
soon i believe
yiming2000 ( Date: 27-Jun-2012 21:12) Posted: |
why fri?
infancybird ( Date: 27-Jun-2012 16:36) Posted:
|
What a Bargain...PE x   12  compare to Q& M which is absurdly high at super-incredible PE  x 45 
#BioSensors: DBSV quotes ‘What a Bargain!’ on grp’s share price, with a Buy
Call and $1.57 TP. House note that share price correction of 12% on various
concerns unwarranted. BIG now trades cheaply at 12x PE, well below the
average of 14.5x PE, and 0.5x PEG.
House believe that BIG’s share price fully reflects the impact of the price
cuts. Sensitivity analysis shows that earnings will still grow at 19% in
FY13F even after factoring a 20% discount to Interventional Cardiology
segment revenue estimate. Furthermore, analysis tells us that BIG’s Europe
exposure is limited to 20% of total revenues. FY13F 20-30% revenue guidance
remains visible. BIG remains a market leader despite increasing
competition. In view, competitors would still need time to establish
themselves as credible threats to BIG.
Growth will primarily be fueled by penetration into rural hospitals in
China and 12 months of consolidation of JWMS’s and Terumo’s licensing. 12x
PE a bargain, reiterate Buy TP1.57.
infancybird ( Date: 27-Jun-2012 16:36) Posted:
|
Yes, it's shorting... CFD... I do not have any stock...  

iPunter ( Date: 27-Jun-2012 16:38) Posted:
|
Ya, I am in the queue to sell @1.16... 

xinru86 ( Date: 27-Jun-2012 16:18) Posted:
|